Covalent Bruton tyrosine kinase inhibitors (BTKis) have improved CLL management, but discontinuation due to adverse events and disease progression remains a challenge. Sequential BCL2 inhibitor ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results